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Site-Specific Glycosylation of an Aglycosylated
Human IgG1-Fc Antibody Protein Generates
Neoglycoproteins with Enhanced Function
which is a major obstacle for the development of thera-
peutic glycoproteins [8].
Immunoglobulin G (IgG) antibodies provide an intri-
guing example of functional diversity orchestrated through
glycosylation [9]. The IgG molecule is a multifunctional
Gregory M. Watt,1 John Lund,2
Michaela Levens,2 V.S. Kumar Kolli,1
Royston Jefferis,2 and Geert-Jan Boons1,*
1Complex Carbohydrate Research Center
The University of Georgia
220 Riverbend Road glycoprotein that binds antigens (pathogens) specifi-
Athens, Georgia 30602 cally to form immune complexes that activate effector
2 Division of Immunity and Infection mechanisms resulting in the clearance and destruction
The Medical School of pathogens. IgG antibodies are comprised of two iden-
University of Birmingham tical antigen binding (Fab) units, which are linked via a
Birmingham, B15 2TJ flexible hinge to the Fc unit (Figure 1). After antigen
United Kingdom binding, the Fc unit can activate a range of effector
responses, which include the complement cascade and
cellular defense mechanisms such as superoxide pro-
duction triggered by binding to Fc receptors. The IgG-
Summary
Fc region is a homodimer comprising interchain disul-
fide-linked hinge regions, glycosylated CH2 domainsA range of well-defined IgG glycoforms was prepared
bearing N-linked oligosaccharides at asparagine 297by employing a combination of synthetic carbohydrate
(Asn-297), and noncovalently paired CH3 domains. Sev-chemistry and genetic engineering. The key aspect of
eral elegant studies [9, 10] have shown that glycosyla-this methodology is the coupling of thioaldoses with
tion of the Fc region is essential for many of its effectorcysteine-containing proteins to give disulfide-linked
functions. There is evidence to suggest that the oligo-neoglycoproteins. This technology was applied to the
saccharides exert their effects through stabilization ofsynthesis of a series of synthetic N-glycan thioaldoses
the protein conformation [11, 12]. In particular, X-raywhich were coupled to an aglycosylated IgG1-Fc frag-
crystallographic studies have shown that the oligosac-ment, engineered to have Cys-297 in place of glycan-
charide is sequestered within the internal space en-linked Asn (h-Fc N297C). Analysis of the resulting Fc
closed by the CH2 domains making multiple contactsneoglycoproteins by mass spectrometry and trypsin
with the protein [13]. A recent X-ray crystallographicdigestion showed that the saccharides were site-
study [14] of an Fc unit bound to a truncated FcRIIIselectively incorporated at Cys-297 to full occupancy
fragment revealed that the N-glycan of the Fc unit formswithout affecting other Fc protein disulfides. The neo-
a contact with the receptor involving a potential hydro-glycoproteins were tested for their ability to interact
gen bond.with human FcRI by inhibiting superoxide production
The oligosaccharide moiety at Asn-297 is of the com-by -interferon-stimulated U937 cells. The neoglyco-
plex biantennary type displaying considerable microhet-proteins displayed enhanced superoxide inhibition rel-
erogeneity. The latter feature seems to be important forative to aglycosylated h-Fc N297C, where increased
Fc-function and disease, and for example, changes inglycan size correlated positively with increased inhi-
glycosylation have been observed for a number of in-bition.
flammatory diseases that include rheumatoid arthritis
[15–17] and systemic vasculitis [18]. Patients with such
Introduction diseases show a deficit in galactosylation resulting in a
high proportion of IgG molecules bearing oligosaccha-
Protein glycosylation is an important cotranslational rides terminating in N-acetyl glucosamine. Immune
modification, which has been implicated as playing ma- complexes formed through these glycoforms can bind
jor roles in modulating protein folding and stability, cell- mannan binding lectin, thereby activating a pseudoclas-
cell communication and receptor binding [1–6]. As oligo- sical complement cascade [16].
saccharide synthesis is not under direct genetic control, There is an urgent need for a method that enables the
ensuing protein glycosylation results in the formation of production of a wide variety of homogenous glycoforms
a heterogeneous range of glycoforms that possess the of recombinant IgG. Such approaches would not only
same peptide backbone but differ in the nature and site be of great use to determine biological roles of individual
of glycosylation. It has been suggested that variations glycoforms but would also be valuable for the produc-
in saccharide substitution is a means of fine-tuning bio- tion of therapeutic antibodies.
activity of glycoproteins [7]. However, due to difficulties We report here a novel approach for obtaining a range
of obtaining well-defined glycoforms, it has only been
of well-defined glycoforms of IgG1-Fc by asymmetric
possible in a few cases to determine the biological roles
disulfide conjugation between synthetic thioaldoses and
of individual glycoforms. Furthermore, it is difficult in
a recombinant IgG-Fc protein having its natural aspara-
general to control glycoform formation in cell culture,
gine glycosylation site replaced with a cysteine residue.
The effector capabilities of the resulting Fc neoglycopro-
teins were evaluated by their ability to interact with hu-*Correspondence: gjboons@ccrc.uga.edu
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Figure 1. Schematic Representations of Hu-
man IgG1 and Truncated Hingeless Fc
The representation of the intact IgG1 struc-
ture is taken from [42]. Truncated hingeless
Fc (h-Fc N297C) (residues 231–447 of the
heavy chains) contains the CH2 and CH3 do-
mains, but lacks the hinge region (residues
216–230) and the complex oligosaccharide
moieties attached to residue 297. The two
heavy chains are held together by noncova-
lent pairing of the CH3 domains.
man Fc -receptor I by inhibiting a superoxide burst site-selective glycosylation of the protein was achieved,
the resulting thioacetamide glycan-protein linkage isfrom -interferon-stimulated U937 cells.
longer by two atoms than the natural linkage to aspara-
gine. With this increased linkage length it may not beResults and Discussion
possible to reproduce contact points between oligosac-
charide and peptide chain which have been found to beThe de novo synthesis offers a promising approach to
well-defined glycoforms of glycoproteins, and several important in IgG [31]. We have shown that a disulfide
linkage between a thioaldose and cysteine can adopt amethods have been explored, each representing unique
and difficult challenges [19]. The chemical synthesis of conformation similar to that of the trans amide linkage
often found in natural N-linked glycoproteins, and theglycoproteins using standard peptide synthesis is only
feasible for peptides smaller than 30 amino acid resi- unusual cis conformation found in IgG [32]. Thus, it was
envisaged that a range of functional and homogenousdues. State of the art native ligation techniques [20]
make it possible to couple (glyco)peptide fragments to glycoforms of IgG could be obtained by coupling syn-
thetic nitropyridinesulfenyl thioglycosides to a Fc unitafford more complex glycopeptides [2, 21–25]. While
synthetic glycopeptides and glycoproteins have proven engineered to have Cys-297 in lieu of glycan-linked Asn
residue (h-Fc N297C). The considerable challenge ofto be indispensable probes for glycobiology, parallel
efforts toward the synthesis of glycopeptide and glyco- this endeavor would be the quantitative incorporation
of not only a monosaccharide but also oligosaccharidesprotein mimetics are being undertaken [24]. These ana-
logs may have improved pharmacokinetic properties of increasing complexity into a recombinant protein that
has several disulfide linkages. Subsequent structuraland are invaluable tools for understanding carbohy-
drate-lectin interactions, proximal peptide-sugar con- analysis should establish the site specificity of the conju-
gation, and biological experiments should determineformational requirements, and the synthesis of immu-
nostimulating glycoconjugates [4, 24, 26–28]. Most whether the saccharide exerts any specific biological
effects.synthetic targets, however, have been rather small with
respects to peptide length, representing fragments of To this end, a range of thioaldoses (6–9) derived from
N-linked glycan oligosaccharides (Figure 2) was pre-glycoproteins several orders of magnitude larger in size.
Previously we communicated [29] a novel approach pared from the corresponding acetylated hemiacetal de-
rivatives (1–4) by treatment first with a 1:2 mixture offor site-selective coupling of saccharides to proteins by
the condensation of a nitropyridinesulfenyl thioglyco- thionyl chloride and toluene yielding the corresponding
-chlorides, which were subsequently taken up in ace-side with a free thiol of a cysteine residue of a peptide
or protein. This approach exploits the fact that cysteines tone containing potassium thioacetate. The resulting
-thioacetate derivatives were treated with sodiumin proteins are normally present as disulfides. An addi-
tional cysteine moiety with a free thiol can, however, be methoxide in methanol to afford the N-glycan thio-
aldoses 6–9 in yields of 40%–70%. A maltopentaoseintroduced at any point of a polypeptide chain by site-
directed mutagenesis. The resulting highly nucleophilic thioaldose 10 was synthesized from peracetylated mal-
topentaose 5 for use as a control compound.thiol can then be reacted with a sugar bearing an electro-
philic moiety to give a well-defined neoglycoprotein. In Although the nitropyridinesulfenyl thioglycoside of
GlcNAc could easily be obtained from 6 [29], the prepa-a seminal study, Flitsch and coworkers have coupled a
monosaccharide bearing an iodoacetamide group to a ration of similar derivatives of more complex sugars
proved problematic. In a search for an alternative ap-human erythropoietin cysteine mutant [30]. Although
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aldose homodisulfide and glutathione disulfide in a sta-
tistical 2:1:1 ratio as determined by 1H-NMR. When a
larger excess of thioaldose 7 was used, only glycopep-
tide 11 and the sugar homodimer were present. Bovine
serum albumin (BSA) was chosen as a model protein
on the merit of its availability and convenience of having
a single cysteine at position 58 of its protein sequence.
After treatment of BSA with excess of 7 in aqueous
ammonium acetate, the BSA-containing fractions were
isolated free from excess 7 and other low molecular
weight by-products by ultrafiltration (Figure 3). The ex-
cess of saccharide could be isolated as a disulfide from
the filtrate by size exclusion column chromatography
over P-2. Thiol concentration analysis of conjugate 12
using dithiodipyridine [33] gave a very low absorbance,
indicating the absence of any free thiols, suggesting that
the conjugation was quantitative. Further spectroscopic
corroboration of conjugate 12 came from MALDI-TOF
mass spectrometry, which showed a mass increase for
conjugate 12 over BSA sample of 477 Da while the theo-
retical difference is 438 Da.
Having established a convenient procedure for the
glycosylation of cysteine moieties of proteins, attention
was focused on the glycosylation of an IgG-Fc fragment.
Deleting the domains encoding for the Fab and hinge
regions from the IgG genetic sequence created a trun-
cated Fc unit glycoprotein (h-Fc). Further engineering
to incorporate Cys-297 in place of the glycan binding
Asn-297 gave aglycosylated cysteine mutant h-Fc
N297C [34] (Figure 1). Epitope mapping using an exten-
sive panel of monoclonal antibodies directed against
the human IgG1 antibody revealed that neither the addi-
tional cysteine at residue 297 nor the absence of carbo-
hydrate caused any large-scale structural changes in-
cluding intradomain disulfide bond formation in the
h-Fc N297C mutant, relative to h-Fc [34]. The ratio-
nale for engineering a hingeless Fc was to absent resi-
dues Cys-226 and Cys-229 within the hinge, which might
otherwise compete with Cys-297 for glycosylation by
thioaldoses. Theh-Fc proteins were analyzed for purityFigure 2. Glycosylation of a Hingeless Fc Cysteine Mutant with
Thioaldoses and molecular composition by mass spectrometry and
SDS-PAGE. Q-TOF mass spectrometry of h-Fc showedConversion of peracetylated hemiacetals 1–5 to the corresponding
thioaldoses 6–10 and their subsequent glycosylation of a hingeless three peaks at 25,813; 25,976; and 26,138 Da (Table 1)
Fc cysteine mutant (h-Fc N297C) to produce disulfide-linkedh-Fc corresponding to fucosylated glycoforms containing 0,
N297C-neoglycoconjugates 13–17, respectively. Conditions: (i) (a) 1, and 2 galactose residues (G0, G1, and G2), respec-
SOCl2, (b) KSAc, (c) NaOMe/MeOH; (ii) (a) 30% w/v HBr in AcOH, tively. These average mass values are close to those(b) KSAc, (c) NaOMe/MeOH; (iii) 1% h-Fc N297C (w.r.t. thioaldose
calculated from the peptide sequence less the N-termi-concentration), aqueous 12.5 mM ammonium acetate pH 8.5, 37C.
nal lysine, which is lost during protein synthesis and
processing [35], and formate incorporation, which can
proach to disulfide-linked neoglycoproteins, a direct occur sometimes during protein mass spectroscopic
coupling of a thioaldose (e.g., 6–10) with a cysteine resi- analysis. As expected, SDS-PAGE of h-Fc showed a
due thiol group was considered. The aerial oxidation of single band of 27 kDa, but h-Fc N297C produced two
thiols to disulfides is thought to occur via a free radical bands at 25 and 50 kDa (Figure 4) [34]. As only the 25
mechanism, where radicals generated from thiolates kDa band was visible when the disulfide bonds of h-Fc
and super oxide form disulfides, but analogous thiol N297C were reduced with -mercaptoethanol, it was
groups are less susceptible to free radical oxidation. deduced that the cysteine 297 had formed a disulfide
Thus, it was expected that treatment of a cysteine-con- linkage with its counterpart causing covalent dimeriza-
taining peptide or protein with an excess of a thioaldose tion of the two heavy chains. The dimerization was con-
at relatively high pH would lead to the formation of a firmed by MALDI-TOF mass spectrometry, displaying
mixed disulfide. Indeed, the combination of equimolar peaks at 24,456 and 48,913 corresponding to the mono-
amounts of thioaldose 7 and reduced glutathione in and dimeric forms of h-Fc N297C, respectively. The
aqueous 23 mM ammonium acetate at pH 8.5 yielded more exposed unnatural disulfide bond could be selec-
tively reduced by treatment with mild reducing agentthe disulfide-linked glycopeptide 11 (Figure 3), the thio-
Chemistry & Biology
810
Figure 3. Preparation of Disulfide-Linked
Neoglycopeptides and Neoglycoproteins
The coupling of thioaldose 7 with the cysteine
thiol groups of glutathione and BSA to pro-
duce the corresponding disulfide-linked neo-
glycopeptide 11 and neoglycoprotein 12, re-
spectively.
cysteamine as determined by SDS-PAGE (Figure 4) and first place. To address this important issue, the chitobi-
ose glycoconjugate 14 was subjected to trypsin diges-Q-TOF mass spectrometry (Table 1). Reaction of the
resulting protein with thiochitobiose 7 afforded a prod- tion and the resulting peptide fragments analyzed by
MALDI-TOF mass spectrometry. Detection of a peak atuct that had an increased mass of 412 Da, indicating
that the Fc neoglycoconjugate 14 had been formed. 1618.1 Da corresponding to the glycosylated peptide of
the predicted cleavage peptide (293–301) EEQYCSTYRUnfortunately, the yield of the conjugation was relatively
low (20%), and it was found that loss of protein was of mass 1178.5 Da  thiochitobiose (1616.6 Da) con-
firmed that glycosylation had occurred at the correctmainly due to the two purification steps required after
reduction and glycosylation. position. Furthermore, a peak at 2332.1 Da correlating
to the predicted peptide fragment containing the C261–In an attempt to improve the conjugation yield, the
unreduced protein was coupled directly with chitobiose C321 cystine-bridge (256–274  321–322) TPEVTC(CK)
VVVDVSHEDPEVK of mass 2330.2 Da, which indicatedthioaldose 7. It was expected that in this reaction, a thiol
disulfide interchange reaction between dimeric protein that this disulfide bond had remained intact during
glycosylation. Although no peak could be found corre-and excess 7 would give the expected product. Indeed,
Q-TOF MS showed a peak at 24,594 Da correlating with sponding to the peptide fragment containing the C367–
C425 cysteine bridge, the absence of peaks correspond-the incorporation of a thiochitobiose moiety. The mass
spectrum showed no peaks for the aglycosylated and ing to glycosylated fragments containing C367 and C425
indicated that no unspecific glycosylation had occurred.additionally glycosylated proteins, indicating that the
conjugation had gone to completion and that only one In addition, tryptic digest of h-Fc did also not show the
C261–C321 cystine bridge or corresponding reducedsaccharide moiety had been incorporated for each
heavy chain fragment. Gratifyingly, the direct thioaldose peptides. Selective reduction and alkylation of h-Fc
N297C, followed by trypsin digestion produced a peak atglycosylation resulted in a greatly improved yield of 60%
of the isolated neoglycoconjugate 14. 1236.2 Da corresponding to alkylated peptide fragment
(293–301) EEQYCSTYR of mass 1178.5 Da  acetamideAs h-Fc N297C contains cystine disulfide bridges
C261–C321 and C367–C425, it could not be established (1235.5 Da).
Having established an efficient conjugation approach,at this point whether these cystine groups had been
glycosylated by 7 or had been formed correctly in the h-Fc N297C was treated with thioaldoses 6, 8, 9, and
Table 1. Mass-Spectral Analysis of h-Fc Proteins: h-Fc, h-Fc N297C, and Homogeneous h-Fc-Neoglycoconjugates 13–17
MALDI-TOF Q-TOF Calculated
h-Fc-Protein Mass (Da) Mass (Da) Massc (Da)
h-Fc N297C 24,456; 48,913a 24,356 24,356
h-Fc N297C reduced 24,478 24,431b 24,432
[-SGlcNAc] 13 24,693 24,593 24,591
[-S(GlcNAc)2] 14 24,868 24,793 24,794
[-S(GlcNAc)2Man] 15 25,030 — 24,956
[-S(GlcNAc)2Man3] 16 25,393 — 25,281
[-SGlc5] 17 25,213 — 25,198
h-Fcd — 25,813e 25,812
25,976f 25,974
26,138g 26,136
ExPASy-calculated average molecular weight of aglycosylated h-Fc peptide sequence, less N-terminal lysine (128.2 Da) and incorporation
of formate (27 Da) 	 24366.5.
a Observed mass of dimer protein.
bh-Fc N297C coupled with cysteamine (76 Da).
c ExPASy calculated average molecular weight of peptide sequence, less N-terminal lysine (128.2 Da) and incorporation of formate (27 Da).
d Glycan is fucosylated N-glycan octasaccharide.
e N-glycan octasaccharide with 0 Gal residues.
f N-glycan octasaccharide with 1 Gal residue.
g N-glycan octasaccharide with 2 Gal residues.
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glycoprotein 13, having a disulfide-linked N-acetyl glu-
cosamine moiety showed no improvement in inhibitory
activity; however, 14–16, having a di-, tri-, or pentasac-
charide attachment, respectively, were markedly better
inhibitors. Furthermore, the activity improved with in-
creasing complexity of the attached carbohydrate. To
demonstrate that the enhanced biological properties of
the neoglycoconjugates were not the result of indirect
steric effects attributed to the bulk of the attached sugar,
maltopentose thioaldose 10 was conjugated to h-Fc
N297C to afford neoglycoprotein 17. Although glycosyl-
ation of h-Fc N297C with 10 produced slightly higher
Figure 4. Reduction of h-Fc N297C with Mild Reducing Agent superoxide inhibition, it displayed much poorer inhibi-
Cysteamine tion than the pentasaccharide neoglycoprotein 16, dem-
SDS-PAGE of h-Fc (lane 2) and h-Fc N297C (lane 3) reduced with onstrating the importance of the nature of the glycan
-mercaptoethanol and unreduced h-Fc N297C (lane 4). Incuba-
structure (Figure 5). The pentasaccharide neoglyconju-tions of h-Fc N297C with mild reducing agent cysteamine at con-
gate 16 was, however, not as active as the wild-typecentrations 0, 0.02, 0.2, 2, and 20 mM are shown in lanes 5–9,
glycosylated h-Fc. The latter glycoprotein contains oli-respectively.
gosaccharides that are much more complex, pos-
sessing between 8 and 12 monosaccharide residues
10 (Figure 2). In each case, mass spectrometry of the with the majority having a fucoside and one or two galac-
purified conjugates 13, 15, 16, and 17, respectively, tosides in addition to the outer-arm N-acetyl glucos-
showed the expected increase in mass (Table 1). The amine residues. It is well known that the presence of
successful preparation of these neoglycoproteins dem- these residues improve IgG effector functions, and for
onstrate for the first time that by in vitro glycosylation, example, it has been shown galactosylation of the outer-
complex oligosaccharides can be incorporated in a site- arm GlcNAc residues accounts for significant increases
specific manner into a recombinant protein that has its in FcRI activity [10, 38] and the effect of outer-arm
natural N-linked glycosylation site replaced by cysteine. sialylation may either be additive or synergistic [39].
Previously, the site-specific glycosylation of protein cys- Thus, it is to be expected that the attachment of more
teines only involved monosaccharides [30, 36] and the complex oligosaccharides to h-Fc N297C will lead to
more simple chitotriose [37]. conjugates with further improved biological activities.
The h-Fc N297C neoglycoproteins 13–17 were ex- The in vitro glycosylation technology described here
amined for their ability to interact with human FcRI offers several distinct advantages for the preparation of
present on U937 leukocyte cells and the results were well-defined glycoforms of glycoproteins. In particular,
compared to h-Fc. A 2 day incubation of U937 cells synthetic oligosaccharides can be incorporated that are
with -interferon enhances cell-surface expression of of low natural abundance but which are known to display
FcRI required for the superoxide burst elicited by U937 exceptional bioactivities. For example, IgG glycoforms
cells upon interaction with IgG1-sensitized JY cells. The that possess a bisecting GlcNAc moiety have a 50-fold
interaction of FcRI with the Fc regions of the IgG anti- increased FcRIII activity but in general are present in
bodies present on the JY cells triggers the superoxide very low natural abundance [40]. Thus, even in the case
burst, which can be inhibited by IgG and by Fc. As that neoglycoconjugation will produce glycoproteins
expected, effective inhibition of the superoxide burst that are not as active as their natural-linked counter
was observed for the glycosylated h-Fc (Figure 5). The parts, improved bioactivities can be obtained by attach-
aglycosylated h-Fc N297C was found to be an almost ment of oligosaccharides that are known to induce high
100-fold worse inhibitor, demonstrating that glycosyla- biological activities. In vitro glycosylation can provide
quantitative incorporation of oligosaccharides, whereastion is of critical importance for FcRI binding. The neo-
Figure 5. Inhibition of Superoxide Produc-
tion with Glycosylated, Aglycosylated, and
Neoglycosylated h-Fc
Inhibition of superoxide production by U937
cells triggered by IgG1-sensitized JY cells
with glycosylated, aglycosylated, and neo-
glycosylatedh-Fc:h-Fc,h-Fc N297C and
homogeneous h-Fc-neoglycoconjugates 13–
17. Superoxide inhibition is represented as
the K50 inhibitory value in nanomolars for each
Fc-protein, whereby the average has been
calculated (SEM given for n 	 3).
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Protein concentrations were determined using a Lowery proteinvariable and fractional occupancies may be observed
concentration kit from Sigma, where UV absorption was recordedin glycoproteins obtained by cell culture. For example,
at 690 nm using a Finstruments 96-well ELISA-plate reader. Thiolrecombinant IgG proteins and their truncated forms pro-
concentrations were determined using purified S,S-dithiodipyridine
duced by mammalian cells can in some cases have as as described by Grassetti and Murray [33], and the absorption was
little as one-third of their heavy chain Asn-297 residues recorded at 340 nm using a Finstruments ELISA-plate reader. Mass
glycosylated [31, 34]. In vitro glycosylation allows more spectra were obtained using a Micromass Q-TOF-2 mass spectrom-
eter and a Hewlett Packard G2025A MALDI-TOF mass spectrometerefficient bacterial or yeast protein expression systems
in positive mode using sinapinic acid as the matrix unless statedto be used, which due to lack of protein glycosylation
otherwise. High-resolution mass spectra were obtained using a Voy-and glycan remodeling, respectively, are not applicable
ager delayed extraction STR with 2,5-dihydroxybenzoic acid as anto the production of mammalian glycoproteins. Also, the
internal calibration matrix. Construction of the pEE14 h-Fc and
incorporation of unnatural oligosaccharide residues will pEE14 h-FcNC297 expression vectors and their transfection into
be possible which may lead to neoglycoconjugates that CHO-K1 cells has been described previously [34]. The chemical
have improved biostabilities. A synthetic strategy will synthesis of the N-glycan core tri- and pentasaccharide structures
will be described elsewhere. 2-acetamido-2-deoxy--D-glucopyr-also make it possible to attach toxins or other reagents
ano-thioaldose 6 was synthesized as described previously [29].to provide neoglycoproteins with novel effector func-
tions.
2-Acetamido-2-Deoxy--D-Glucopyranosyl-(1-4)-2-
Acetamido-2-Deoxy--D-Glucopyrano-Thioaldose (7)Significance
A stirred suspension of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-
-D-glucopyranosyl-(1-4)-2-acetamido-3,6-di-O-acetyl-2-deoxy-
Mammalian glycoprotein biosynthesis produces a het- D-glucopyranose 2 (100 mg, 0.16 mmol) in a 1:1 mixture of anhy-
erogeneous range of proteins that possess the same drous DCM and anhydrous toluene (1 ml) was treated with thionyl
chloride (1.5 ml) at room temperature for 2 hr. Removal of the solventpeptide backbone but differ in the nature and site of
and reagent under reduced pressure gave the -chloride derivative,glycosylation. This feature has frustrated efforts to
which was subsequently taken up in acetone (6 ml) containing potas-elucidate biological functions of glycoproteins, in par-
sium thioacetate (26 mg, 0.23 mmol). The resulting mixture wasticular in those cases in which the precise structure
stirred at room temperature for 18 hr, and the solvent was removed
of a glycan determines biological activity. Further- under reduced pressure. Flash-column chromatography of the resi-
more, the inability to control N-glycan formation in due using a 2%–6% gradient of methanol in DCM afforded the
cell culture is a major obstacle in the development peracetylated thioaldose (44 mg), which was treated with a 0.5 M
solution sodium methoxide in methanol (5 ml) for 30 min. After neu-of therapeutic glycoproteins. Although chemists have
tralization of the reaction mixture using Amberlite 650C ion ex-made good progress toward the chemical synthesis
change resin, the solvent was removed in vacuo to give the titleof native well-defined glycopeptides, the preparation
compound 7 (28 mg, 40%) as a white solid; 1H NMR (D2O, 600 MHz)of even a small glycoprotein is a formidable task. We

 4.53 (d, 1H, J1-2 	 10.3 Hz, H-1), 4.44 (d, 1H, J1-2 8.3 Hz, H-1),have demonstrated that a recombinant protein that 3.77 (dd, 1H, J5-6b 1.9, J6a-6b 12.2 Hz, H-6b), 3.68 (dd, 1H, J5-6b 2.0,
has its natural N-linked glycosylation site replaced by J6a-6b 12.2 Hz, H-6b), 3.64 (t, 1H, J 9.8 Hz, H-2), 3.60 (dd, 1H, J5-6a
cysteine can be glycosylated with complex synthetic 5.4 Hz, H-6a), 3.60 (dd, 1H, J2-3 10.3 Hz, H-2), 3.52 (dd, 1H, J2-3
9.7, J3-4 8.8 Hz, H-3), 3.49 (m, 1H, H-4), 3.49 (dd, 1H, J5-6a 5.4 Hz,oligosaccharides to give disulfide-linked glycopro-
H-6a), 3.42 (dd, 1H, J3-4 8.3 Hz, H-3), 3.38 (m, 1H, H-5), 3.34 (m,teins. This technology was applied to the glycosylation
1H, H-5), 3.32 (dd, 1H, J4-5 9.8 Hz, H-4), 1.92 and 1.89 (2  s, 6H,of an IgG1-Fc fragment, engineered to have Cys-297 in
2  COCH3); MALDI-TOF MS (with 2,5-dihydroxybenzoic acid asplace of glycan-linked Asn, where mass spectrometric
matrix): 461.9 (MNa) and 477.9 (MK); HR MS (m/z): calcd for
analysis combined with protease digestion indicated C16H28N2NaO10S 463.1337, found 463.1362.
that oligosaccharides as complex as a pentasacchar-
ide could be attached in a site-specific manner. The -D-Mannopyranosyl-(1-4)-2-Acetamido-2-Deoxy-
resulting neoglycoproteins were tested for their ability -D-Glucopyranosyl-(1-4)-2-Acetamido-2-Deoxy-
-D-Glucopyrano-Thioaldose (8)to interact with human FcRI by inhibiting superoxide
2,3,4,6-tetra-O-acetyl--D-mannopyranosyl-(1-4)-2-acetamido-3,6-production by -interferon-stimulated U937 cells. These
di-O-acetyl-2-deoxy--D-glucopyranosyl-(1-4)-2-acetamido-3,6-di-O-studies showed for the first time that the biological
acetyl-2-deoxy-D-glucopyranose 3 (52 mg, 54 mol) was subjectedactivity of a glycoprotein lost by removal of its natural
to identical experimental conditions as for compound 7 to give the
glycosylation site can be restored partially by the in title compound 8 (22 mg) in 41% yield; 1H NMR (D2O, 500 MHz) 
 4.60
vitro attachment of synthetic saccharides. Although (s, 1H, H-1″), 4.50 (d, 1H, J1-2 10.3 Hz, H-1), 4.42 (d, 1H, J1-2 7.6 Hz,
the neoglycoconjugates were not as active as the cor- H-1), 3.88 (d, 1H, J2″-3″ 3.4 Hz, H-2″), 3.81 (dd, 1H, J5″-6b″ 2.0, J6a″-6b″ 12.2
Hz, H-6b″), 3.77 (dd, 1H, J5-6b 2.0, J6a-6b 12.3 Hz, H-6b), 3.71 (dd, 1H,responding N-linked glycoprotein, it is to be expected
J5-6b 2.0, J6a-6b 12.3 Hz, H-6b), 3.69–362 (m, 5H, H-2, H-2, H-3, H-4that further improvements of activity can be obtained
and H-6a), 3.61 (dd, 1H, J5″-6a″ 6.8 Hz, H-6a″), 3.55–3.50 (m, 4H, H-3,be employing more complex oligosaccharides. In vitro
H-4, H-6a and H-3″), 3.50 (m, 1H, H-5), 3.45 (dd, 1H, J3″-4″ 9.3, J4″-5″ 9.8glycosylation of recombinant proteins offers several
Hz, H-4″), 3.34 (m, 1H, H-5), 3.30 (m, 1H, H-5″), 1.94 and 1.93 (2  s,
distinct advantages, including quantitative conjuga- 6H, 2  COCH3); MALDI-TOF MS (with 2,5-dihydroxybenzoic acid as
tion of oligosaccharides, the incorporation of oligo- matrix): 624.7 (MNa) and 640.7 (MK); HR MS (m/z): calcd for
saccharides that are of low natural abundance but C22H38N2NaO15S 625.1855, found 625.1891.
which are known to display high bioactivities, and the
possibility of using more efficient bacterial or yeast -D-Mannopyranosyl-(1-6)[-D-mannopyranosyl-(1-3)]--D-
Mannopyranosyl-(1-4)-2-Acetamido-2-Deoxy--D-protein expression systems.
Glucopyranosyl-(1-4)-2-Acetamido-2-Deoxy--D-
Glucopyrano-Thioaldose (9)Experimental Procedures
2,3,4,6-tetra-O-acetyl--D-mannopyranosyl-(1-6)-[2,3,4,6-tetra-O-
acetyl--D-mannopyranosyl-(1-3)-]-2,4-di-O-acetyl--D-mannopyran-General Experimental Details
osyl-(1-4)-2-acetamido-3,6-di-O-acetyl-2-deoxy--D-glucopyranosyl-Chemicals were purchased from Acros (Pittsburgh, PA) or Aldrich
(Milwaukee, WI), Sigma (St. Louis, MO), and Fluka (Milwaukee, WI). (1-4)-2-acetamido-3,6-di-O-acetyl-2-deoxy-D-glucopyranose 4 (38
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mg, 25.6 mol) was subjected to identical experimental conditions as ately incubated with thioaldose (50 equivalents) as described below.
Alternatively, for analytical purposes, the selectively reduced h-Fcfor compound 7 to give the title compound 9 (16 mg, 41%) as a white
solid; 1H NMR (D2O, 500 MHz) 
 4.92 (s, 1H, H-1″), 4.72 (s, 1H, H-1″″), N297C was treated with iodoacetamide (final concentration 40 mM) to
quench any remaining cysteamine and to alkylate the cysteine groups4.61 (s, 1H, H-1″), 4.52 (d, 1H, J1-2 11.0 Hz, H-1), 4.44 (d, 1H, J1-2 7.7
Hz, H-1), 4.08 (d, 1H, J2″-3″ 3.4 Hz, H-2″), 3.89 (m, 1H, H-2″), 3.79 (m, preventing reformation of the undesired disulfide bond. The alkylated
protein was subjected to SDS-PAGE and trypsin digestion as de-1H, H-2″″), 3.78–3.66 (m, 8H), 3.66–3.51 (m, 10H), 3.51–3.42 (m, 6H),
3.42–3.30 (m, 3H), 1.92 and 1.89 (2  s, 6H, 2  COCH3); MALDI-TOF scribed below for compound 14.
MS (with 2,5-dihydroxybenzoic acid as matrix): 949.9 (MNa) and
965.8 (MK); HR MS (m/z): calcd for C34H58N2NaO25S 949.2898, found Formation of of h-Fc N297C Neoglycoproteins (13–17)
949.2947. To a 20 nM solution ofh-Fc N297C in PBS (50l) was added aqueous
thioaldose (50 equivalents) and 0.25 M ammonium acetate at pH 8.5
(8 l). The resulting mixture was incubated with occasional agitation-D-Glucopyranosyl-(1-4)--D-Glucopyranosyl-(1-4)--D-
at 37C for 5 hr, whereupon a second portion of the thioaldose (50Glucopyranosyl-(1-4)--D-Glucopyranosyl-(1-4)--D-
equivalents) solution was added. After 16 hr at 37C, the mixture wasGlucopyrano-Thioaldose (10)
subjected to microdialysis against water for 2 hr using Pierce Microdia-Peracetylated maltopentaose 5 (36 mg, 24 mol) in DCM (0.6 ml) was
lysis devices fitted with 10 kDa cutoff membranes. The neoglycoconju-treated with a 30% solution of HBr in acetic acid (0.5 ml) for 4 hr
gates were analyzed by MALDI-TOF MS and Q-TOF MS and theirbefore dilution with DCM (15 ml) washing in-turn with ice/water (10
concentrations determined using the Lowery assay [41].ml), saturated solution of sodium bicarbonate (10 ml) and ice/water
(10 ml), drying (MgSO4), and removal of the solvents under reduced
pressure. The resulting glycosyl bromide (26 mg, 17 mol) was treated Trypsin Digest of Chitobiose Fc-Neoglycoprotein (14)
with acetone (2 ml) containing potassium thioacetate (2.5 mg, 22.1 The chitobiose neoglycoconjugate 14 (20 nM) in PBS (25 l) was sub-
mol), and the resulting mixture was stirred at room temperature for jected to microdialysis against 25 mM ammonium acetate (pH 7.4) for
18 hr; thereafter, the solvent was removed under reduced pressure. 1 hr using a Pierce Microdialysis device fitted with a 10 kDa cutoff
Flash-column chromatography (gradient of 2%–6% methanol in DCM) membrane. The resulting neoglycoconjugate solution was treated with
of the residue afforded the peracetylated thioaldose, which was a solution of sequencing grade trypsin from Sigma (1 mg/ml) in 1 mM
deacetylated as described above to give the title compound 10 (21 HCl (1 l) at 37C for 24 hr, whereupon the mixture was subjected to
mg, 80%) as a white solid; 1H NMR (D2O, 500 MHz) 
 5.29 (m, 4H, H-1, MALDI-TOF MS using -cyano-4-hyroxy cinnamic acid as the matrix.
H-1″, H-1″ and H-1″″), 4.46 (d, 1H, J1-2 9.3 Hz, H-1), 3.87–3.79 (m, 3H), A 20 nM solution of the selectively reduced and alkylated h-Fc N297C
3.79–3.68 (m, 10H), 3.68–3.45 (m, 15H), 3.31 (dd, 1H, J2-3 9.3, J3-4 9.8 subjected to identical sequencing conditions was used as a control.
Hz, H-3) and 3.18 (t, 1H, J 9.3 Hz, H-2); MALDI-TOF MS (with 2,5-
dihydroxybenzoic acid as matrix): 844.6 (MNa) and 860.5 (MK); Superoxide Burst Inhibition Assay
HR MS (m/z): calcd for C34H58N2NaO25S 867.2386, found 867.2416. U937 cells were pretreated with-IFN (1000 U/ml) for 2 days; thereafter,
the cells were washed and resuspended at 2  106 cells/ml in Hanks
balanced salt solution (HBSS) containing BSA (15 M). Target JY cells2-Acetamido-2-Deoxy--D-Glucopyranosyl-(1-4)-2-
both lacking (baseline control) and sensitized with a humanized IgG1Acetamido-2-Deoxy-1-Thio--D-Glucopyrano-
(20 nM) were washed and resuspended at 2  107 cells/ml in HBSS/S-S-Glutathione Disulfide (11)
BSA. U937 cells (2  105 cells/ml), the appropriate concentration ofA solution (20 ml) of 2-acetamido-2-deoxy--D-glucopyranosyl-(1-4)-
inhibitor (0.2–200 nM for h-Fc and 2.0–2000 nM for h-Fc N297C and2-acetamido-2-deoxy--D-glucopyrano-thioaldose 7 (5 mg, 11.0 M)
neoglycoconjugates 13–17) and lucigenin (250 M) were incubated forand glutathione (1.7 mg, 5.7M) in aqueous 25 mM ammonium acetate
5 min at 37C. JY cells were added (2  106 cells/ml) to initiate theat pH 8.5 was stirred at room temperature for 18 hr. The reaction
assay and superoxide production was measured as lucigenin-mixture was freeze-dried and the disulfide-linked glycopeptide 11 (3.2
enhanced chemiluminecence for 30 min at 37C using a Bertholdmg, 76%) was isolated by P-2 gel-filtration (water as eluent). 1H NMR
LB953 luminometer [34]. The chemiluminecence response curve area(D2O, 500 MHz) 
 4.80 (dd, 1H, J 3.9 and 9.8 Hz, CH-Cys), 4.62 (d, 1H,
values were plotted against inhibitor concentration using MicrosoftJ1,2 10.7 Hz, H-1), 4.58 (d, 1H, J1,2 8.9 Hz, H-1), 4.04 (dd, 1H, J2,3 9.8
Excel to create an inhibition curve from which the inhibition constant,Hz, H-2), 3.91 (dd, 1H, J5,6b 1.9, J6a,6b 11.7 Hz, H-6b), 3.86 (dd, 1H,
IC50 was obtained. Assays were performed in triplicate and the IC50J5,6b 1.9, J6a,6b 11.7, H-6b), 3.69–3.81 (m, 6H, CH2-Gly, CH-Glu, H-2,
results averaged.H-3, and H-6a), 3.66 (dd, 1H, J5,6a 5.9 Hz, H-6a), 3.65 (dd, 1H, J3,4 8.8,
J4,5 9.8 Hz, H-4), 3.55 (dd, 1H, J2,3 10.7, J3,4 8.8 Hz, H-3), 3.54 (m, 1H,
H-5), 3.50 (m, 1H, H-5), 3.46 (dd, 1H, J4,5 9.7 Hz, H-4), 3.36 (dd, 1H, Supplemental Data
J 3.9 and 14.6 Hz, CH2-Cys), 2.99 (dd, 1H, J 9.8 and 14.6 Hz, CH2-Cys), Supplemental data include 1H-NMR spectra of thioaldoses 2–5,
2.52 and 2.15 (2  m, 4H, 2  CH2-Glu), 2.06 and 2.01 (2  s, 6H, 2  Q-Tof mass spectra of h-Fc, h-Fc NC297, h-Fc NC297 (reduced
CH3CO); MALDI-TOF MS (ve): 746.2 (MH), 768.2 (MNa), 784.2 with cysteamine), and h-Fc NC297 neoglycoconjugates 8 and 9,
(MK), and 789.2 (M-H2Na). and superoxide inhibition curves forh Fc NC297 and neoglycocon-
jugates 8–11. The Supplemental Data is available at http://
www.chembiol.com/cgi/content/full/10/9/807/DC1.2-Acetamido-2-Deoxy--D-Glucopyranosyl-(1-4)-2-
Acetamido-2-Deoxy-1-Thio--D-Glucopyrano-
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